Related Experiment Video

Updated: Feb 26, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.3K

Application of Kinase Inhibitors for Anti-aging Intervention

Mercedes Cano1, Antonio Ayala2, Francesco Marotta3

  • 1Department of Physiology, Faculty of Pharmacy, University of Seville, Seville, Spain.

Current Pharmaceutical Design
|July 18, 2017
PubMed

Insights

This review explores using kinase inhibitors for anti-aging interventions to improve healthspan and longevity. It examines the role of Janus kinase (JAK)/STAT and S6Ks pathways in aging and highlights FDA-approved inhibitors.

Area of Science:

  • Biochemistry and Molecular Biology
  • Pharmacology and Drug Discovery
  • Gerontology and Aging Research

Background:

  • Protein phosphorylation, regulated by protein kinases, plays crucial roles in physiological and pathological processes.
  • Targeting protein kinases is a significant focus in pharmaceutical research, particularly for cancer therapy.
  • Emerging evidence suggests kinases are involved in the aging process, presenting opportunities for anti-aging interventions.

Purpose of the Study:

  • To review the impact of phosphoproteomics in understanding disease mechanisms.
  • To discuss the significance of drug discovery approaches targeting kinases.
  • To explore the role of Janus kinase (JAK)/signal-transducing adapter molecules (STAT) and p70 ribosomal protein S6 kinase (S6Ks) pathways in aging and age-related diseases.
  • To examine epidemiological data correlating JAK/STAT and S6Ks expression with cancer and patient outcomes.
  • To present FDA-approved inhibitors targeting these kinases.

Main Methods:

  • Literature review of phosphoproteomic studies.
  • Analysis of drug discovery strategies for kinase inhibitors.
  • Review of studies on JAK/STAT and S6Ks pathway dysregulation in aging.
  • Examination of epidemiological data on kinase expression and cancer outcomes.
  • Compilation of FDA-approved kinase inhibitors.

Main Results:

  • Phosphoproteomics offers insights into molecular mechanisms of diseases.
  • Targeting kinases is a promising strategy in drug discovery.
  • Dysregulation of JAK/STAT and S6Ks pathways is implicated in aging.
  • Epidemiological studies may reveal correlations between kinase expression and cancer.
  • Several kinase inhibitors targeting JAK/STAT and S6Ks pathways are FDA-approved.

Conclusions:

  • Kinase inhibitors represent a potential therapeutic avenue for anti-aging interventions, enhancing healthspan and longevity.
  • Further research into the role of specific kinase pathways like JAK/STAT and S6Ks in aging is warranted.
  • FDA-approved kinase inhibitors offer starting points for developing novel anti-aging drugs.
Keywords:
Protein kinasesS6Kanti-aginghealthspanjanus kinase (JAK)kinase inhibitorlongevityphosphoproteomic

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

580

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.3K